Disposition of 20000 shares by Samarth Kulkarni of Crispr Therapeutics at 19.12 subject to Rule 16b-3
| CRSP Stock | USD 49.72 6.23 14.33% |
Slightly above 55% of Crispr Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that some traders are interested. Crispr Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Crispr Therapeutics AG. Many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Crispr |
Filed transaction by Crispr Therapeutics AG Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Crispr Therapeutics Fundamental Analysis
We analyze Crispr Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Crispr Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Crispr Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crispr Therapeutics stock to make a market-neutral strategy. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics with similar companies.
Peers
Crispr Therapeutics Related Equities
| BEAM | Beam Therapeutics | 13.25 | ||||
| EDIT | Editas Medicine | 12.20 | ||||
| FATE | Fate Therapeutics | 11.81 | ||||
| VERV | Verve Therapeutics | 11.28 | ||||
| NTLA | Intellia Therapeutics | 11.00 | ||||
| CRBU | Caribou Biosciences | 3.05 | ||||
| REGN | Regeneron Pharmaceuticals | 0.1 | ||||
| NVO | Novo Nordisk | 1.22 | ||||
| SRPT | Sarepta Therapeutics | 1.38 | ||||
| KRYS | Krystal Biotech | 1.61 | ||||
| HEPA | Hepion Pharmaceuticals | 10.00 |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.